(Q37109136)

18 August 2017

1 reference

title

Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia (English)

1 reference

18 August 2017

1 reference

Stacy S Shord

1

1 reference

18 August 2017

J M Hamilton

series ordinal

2

1 reference

18 August 2017

Sandra Cuellar

series ordinal

3

1 reference

18 August 2017

publication date

1 March 2008

1 reference

Journal of Oncology Pharmacy Practice

18 August 2017

published in

1 reference

18 August 2017

volume

14

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

5-22

1 reference

Prevalence and outcomes of anemia in cancer: a systematic review of the literature

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

The use of recombinant human erythropoietin to prevent carboplatin-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

The blue cross blue shield assessment technology review: summary of findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Anemia of inflammation: the cytokine-hepcidin link

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

On the relative safety of parenteral iron formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Update on adverse drug events associated with parenteral iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155207087654

21 January 2018

Identifiers

DOI

10.1177/1078155207087654

1 reference

18 August 2017

1 reference